Small molecule drugs such as Lapatinib (a protein tyrosine kinase inhibitor for HER2-positive breast cancer) and Antibody-drug conjugates (ADCs) like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) belong to the second-line drugs [5–7]. Here, ERBB2 is linked to breast carcinoma.